Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CellCept dosing regimens in kidney transplant
NCT00788567Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2005
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mycophenolate mofetil in kidney transplant rejection (2 arms), sponsored by Roche. Primary endpoint: Proportion of patients achieving mycophenolic acid therapeutic window by Day 5. Started Jun 2005; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00788567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00788567.